SCHEMBL19089427

SCHEMBL19089427

C=CC(=O)Nc1cc(Nc2cc(Nc3cc(OC)c(Cl)cc3Cl)ncn2)c(OC)cc1OCCCN1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.52
KDR P35968 7/20 0.52
FGFR1 P11362 3/20 0.49
SRC P12931 3/20 0.47
JAK3 P52333 3/20 0.47
BTK Q06187 3/20 0.47
ERBB2 P04626 2/20 0.47
KIT P10721 2/20 0.47
ERBB3 P21860 2/20 0.47
ERBB4 Q15303 2/20 0.47
ABL1 P00519 2/20 0.47
BCR P11274 2/20 0.47
FLT1 P17948 2/20 0.47
BMPR1B O00238 1/20 0.47
CIT O14578 1/20 0.47
MAP2K7 O14733 1/20 0.47
GAK O14976 1/20 0.47
EPHB6 O15197 1/20 0.47
MAP3K7 O43318 1/20 0.47
RIPK2 O43353 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210259 0.96 EGFR (0.56) EGFRKDRFGFR1
SCHEMBL20548911 0.96 EGFR (0.56) EGFRKDRFGFR1
SCHEMBL19089422 0.95 EGFR (0.55) EGFRKDRFGFR1
SCHEMBL19089421 0.94 FGFR1 (0.55) EGFRKDRFGFR1SRCJAK3
SCHEMBL19089420 0.90 FGFR1 (0.52) EGFRKDRFGFR1SRCERBB2
SCHEMBL35210289 0.90 FGFR1 (0.52) EGFRKDRFGFR1SRCERBB2
SCHEMBL35210305 0.90 FGFR1 (0.47) EGFRKDRFGFR1SRCABL1
SCHEMBL20548767 0.90 FGFR1 (0.47) EGFRKDRFGFR1SRCABL1
SCHEMBL20655722 0.89 EGFR (0.54) EGFRKDRFGFR1SRCJAK3
SCHEMBL20548915 0.86 EGFR (0.56) EGFRKDRFGFR1SRCJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US disclosed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US disclosed
WO-2017114500-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY 恩瑞生物医药科技(上海)有限公司 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy EGFR, ABL1, CSNK1A1 EGFR 1/4885KDR 1299/4885FGFR1 118/4885
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY EGFR, ABL1, CSNK1A1 EGFR 1/4885KDR 1299/4885FGFR1 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.